Singapore Clinical Trial: A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single- and Multiple-Ascending Dose Study to Characterize the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY4088044 in Healthy Participants.

Singapore, March 28 -- The Health Sciences Authority received information related to the study titled 'A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single- and Multiple-Ascending Dose Study to Characterize the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY4088044 in Healthy Participants.'. The following are the other relevant details related to the trial:

Therapeutic Area: Neurology

Trial Centre(s): Lilly Centre for Pharmacology

Trial Status: NA

Principal Investigator(s): Dr Jeffer Hann Wei Pang

Published by HT Digital Content Services with permission from Health Daily Digest....